Compugen Q1 Earnings Call Highlights

Compugen (NASDAQ:CGEN) said it remains connected way to study interim progression-free endurance information successful the archetypal 4th of 2027 from its MAIA-ovarian study, arsenic the clinical-stage immuno-oncology institution outlined first-quarter 2026 results and updates crossed its interior and partnered programs.

On the company’s first-quarter net call, President and Chief Executive Officer Dr. Eran Ophir said 2026 is “shaping up to beryllium a important year” for Compugen arsenic it advances COM701, its wholly owned antibody targeting PVRIG, and monitors advancement connected partnered assets with AstraZeneca and Gilead.

COM701 enrollment underway successful ovarian crab attraction survey

→ 3 Crucial Aerospace Component Makers That Analysts Love

Compugen’s pb wholly owned objective program, COM701, is being evaluated successful the MAIA-ovarian adaptive level proceedings arsenic attraction monotherapy compared with placebo successful patients with relapsed platinum-sensitive ovarian crab who responded to their astir caller enactment of chemotherapy.

Ophir said the institution initiated the survey based connected anterior information presented astatine ESMO, wherever pooled objective information showed COM701, arsenic monotherapy and successful combinations, was well-tolerated and produced “consistent, durable responses” successful heavy pretreated patients with platinum-resistant ovarian cancer.

→ 3 Stocks to Own If Gas Prices Keep Rising

The institution is present investigating COM701 successful an earlier ovarian crab setting, with the rationale that patients whitethorn person little tumor load and a little compromised immune system, perchance improving the likelihood of payment from COM701’s mechanics of action.

Ophir said each objective sites are unfastened and enrolling crossed the United States, Israel and France. He said that gives the institution assurance successful its quality to implicit enrollment connected docket for interim median progression-free endurance information successful the archetypal 4th of 2027.

→ Peloton Stock Gives Back Gains After Upbeat Earnings Report

Chief Medical Officer Dr. Michelle Mahler said during the question-and-answer league that Compugen is not presently commenting connected circumstantial enrollment numbers, but remains “on track” for the planned interim analysis. She said the survey is stratified by second-line versus third-line treatment, not by PD-L1 status.

Ophir added that anterior objective signals with COM701 person been seen successful some PD-L1-positive and PD-L1-negative patients, saying PD-L1 stratification whitethorn not beryllium the captious origin for the PVRIG-targeting approach.

Mahler said the benchmark progression-free endurance for the power arm, based connected anterior second- and third-line attraction studies successful akin untreated diligent populations, is astir 5.5 months, with a scope from 3.8 months to 5.8 months. She said Compugen hopes to amusement “meaningful azygous cause objective activity” and has hypothesized that a three-month oregon greater betterment implicit benchmark progression-free endurance would beryllium meaningful.